Dublin, Nov. 02, 2018 (GLOBE NEWSWIRE) — The “China Human Vaccine Industry Report, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.
The lot release volume of human vaccines has remained at around 650 million doses over the past three years. China Food and Drug Administration (CFDA) approved the launch of 9-valent human papillomavirus vaccine (saccharomyces cerevisiae) and oral 5-valent reassortant rotavirus attenuated live vaccine (Vero cell) in the first half of 2018. The National Institutes for Food and Drug Control, Hubei Institute for Food and Drug Control, and Shanghai Institute for Food and Drug Control approved supply of 434.1 million doses (44 kinds of vaccines) to the market from January to September 2018.
With annual capacity of over one billion doses, more than forty vaccine manufacturers in China are capable of producing 63 kinds of vaccines for prevention of 34 sorts of infectious diseases. Among them, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Changchun Institute of Biological Products, Beijing Bio-Institute Biological Products, Changchun KEYGEN Biological Products, and Beijing Tiantan Biological Products (Beijing Tiantan Biological Products has no vaccine business after completion of asset restructuring in May 2017) under China National Biotech Group Co., Ltd. occupy half of the Chinese vaccine market. The subsidiaries under China National Biotech Group Co., Ltd. recorded lot release volume of 349.147 million doses in 2017 and 198.261 million doses in the first nine months of 2018, making up 53.1% and 45.7% of the country’s total amount, respectively.
In recent years, Chinese vaccine companies have spared no efforts in research and development to sharpen competitiveness. As yet, not a Chinese enterprise can produce HPV vaccines and 13-valent pneumonia vaccines, but local companies including Walvax Biotechnology and Shenzhen Kangtai Biological Products are developing such vaccines which are expected to be available soon.
With the implementation of two-child policy, the aging of population and the launch of new-type vaccines, China’s human vaccine industry will grow steadily in future, with the expected market size of RMB35.2 billion by 2022. Meanwhile, vaccine companies with richer capital and stronger R&D strength will give play to technological superiorities and scale effect, and raise their market share through capital operation and other means. In this sense, China’s vaccine industry tends to feature higher and higher concentration.
China Human Vaccine Industry Report, 2018-2022 highlights the following:
- China’s human vaccine industry (operating environment, status quo, market demand, distribution channels, market size, import and export, and competitive landscape);
- Chinese human vaccine market segments (market demand, lot release volume and competitive landscape);
- 22 human vaccine companies (operation, R&D and investment, development strategy, etc.).
Key Topics Covered:
1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain
2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern
3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.2 Meningococcal Vaccine
3.3 Hepatitis A Vaccine
3.4 Influenza Vaccine
3.5 Hib Vaccine
3.6 Human Rabies Vaccine
3.7 Varicella Vaccine
3.8 Pneumococcal Vaccines
3.9 DTP Vaccine
3.10 Poliomyelitis Vaccine
3.11 Hepatitis E Vaccine
4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine and Serum Institute
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.2 Beijing Tiantan Biological Products Co., Ltd.
4.3 Hualan Biological Engineering Inc.
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.5 Walvax Biotechnology Co, Ltd.
4.6 Liaoning Cheng Da Co., Ltd.
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.8 Changsheng Bio-Technology Co., Ltd.
4.9 Olymvax Biopharmaceuticals Inc.
4.10 Sinovac Biotech Ltd.
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.13 Dalian Hissen Bio-Pharm Co., Ltd.
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.15 Dalian Aleph Biomedical Co., Ltd.
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.17 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.18 Other Enterprises
4.18.1 Xiamen Innovax Biotech Co., Ltd.
4.18.2 Convac Biotechnology Co., Ltd.
4.18.3 Chengdu Kanghua Biological Products Co.,Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc.
5 Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 Human Papillomavirus (HPV) Vaccine Market is Promising
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
For more information about this report visit https://www.researchandmarkets.com/research/hv2kjs/china_human?w=12
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines
